Clinical trials: Stage IA Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer, Pancreatic Cancer
A Study of JMT203 in Patients With Cancer Cachexia
A Phase Ia/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients with Cancer Cachexia
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Cancer Cachexia, Colorectal Cancer Cachexia
- Trial name
- NCT06868849
- Testing
- JMT203 Injection
- Where
- China
- Volunteers
- 307 people
- Sponsor
- Shanghai JMT-Bio Inc.
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
Non-small Cell Lung Cancer
Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung Cancer
This is a non-interventional, multi-country, multicentre, retrospective study designed to determine the treatment patterns and associated survival rate in patients with primary stage IA to IIIB resectable NSCLC diagnosed between…
- Trial name
- THASSOS-INTL (NCT04808050)
- Where
- 25 sites in Australia, Egypt and 5 more
- Volunteers
- 748 people
- Sponsor
- AstraZeneca
Solid Tumors, Non-Small Cell Lung Cancer
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
This is a phase 1a/1b, open-label, multicenter, dose-escalation and dose-expansion study evaluating the safety, tolerability, antitumor activity, pharmacokinetics, and pharmacodynamics of FXB0871 monotherapy in adults with…
- Conditions
- Solid Tumors, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- NCT07558200
- Testing
- Intervention1：FXB0871, Intervention2：FXB0871, Intervention3：FXB0871
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Squamous Non-Small Cell Lung Cancer sqNSCLC
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 in Combination With Ivonescimab in Sq-NSCLC Patients
The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) combination with Ivonescimab in patients with sq-NSCLC.
- Trial name
- NCT07614646
- Testing
- EVM14, Ivonescimab
- Volunteers
- 13 people
- Sponsor
- Everest Medicines (Beijing) Co., Ltd.
Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating…
- Trial name
- NCT06693336
- Testing
- SMS001
- Where
- 2 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- ToLymph Inc.
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
- Trial name
- NCT04449874
- Testing
- GDC-6036, Atezolizumab, Cetuximab
- Where
- 63 sites in United States, Australia and 15 more
- Volunteers
- 498 people
- Sponsor
- Genentech, Inc.
Non-Small Cell Lung Cancer, Lung Cancer, Non-Small Cell
Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
This is a phase 2 open-label, multicenter, non-randomized study to evaluate the safety and efficacy of oral pazopanib as neoadjuvant treatment for patients with stage 1A, 1B, IIA or IIB (to T2) resectable Non-Small Cell Lung…
- Trial name
- NCT00367679
- Testing
- Pazopanib
- Where
- 12 sites in United States, Israel and 1 more
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline